Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectua... (addition Quark's current clinicalpipelin...)

HOME >> MEDICINE >> TECHNOLOGY

Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

Date:9/25/2008

addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA delivered systemically in a human clinical trial.

In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com
Quark Pharmaceuticals, Inc. The Ruth Group (investors / media)

Juliana Friedman Sara Ephraim / Janine McCargo

+972 89 30 5111 (646) 536-7004 / 7033

jfriedman@quarkpharma.com sephraim@theruthgroup.com

jmccargo@theruthgroup.com

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia

Post Your Comments:

(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com ... China Pharmaceutical Guidebook Series (4) 2013 Edition Material ... for Imported Drug Registration: A Guidebook of Registration ... Medicines " to its online database. ... Chinese medicines are always regarded by occidental as ...

(Date:5/22/2013)... and VANCOUVER, British Columbia , May 22, ... a leader in the development of novel therapeutics to target ... trials of its investigational compounds, custirsen and OGX-427, will be ... Annual Meeting of the American Society of Clinical Oncology ... 31 – June 4. Despite the availability ...

(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...

[0] China Pharmaceutical Market Guidebook Series (4) 2013 Report [0] OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [0] Concord Medical Reports First Quarter 2013 Financial Results

... of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the initiation ... molecule compound designed to specifically,target the CCR1 chemokine receptor which is ...

... Business, DUBLIN, Ohio, May 12 Cardinal ... improve the safety and,productivity of health care, today ... privately held Enturia, Inc., the manufacturer of,infection prevention ... ChloraPrep(R) brand products are used widely in U.S. ...

Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4 ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5 Cardinal Health Completes Enturia Acquisition 2

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Cardinal Health Completes Enturia Acquisition

(Date:5/21/2013)... 2013 The University of Colorado’s Anschutz ... HEALTHY DINING to help Coloradans make healthier choices when ... program is called HEALTHY DINING IN COLORADO. More ... participating in Colorado. Restaurants will offer a selection of ... lean protein, vegetables, fruits, whole grains and unsaturated fats. ...

(Date:5/21/2013)... May 22, 2013 Swimsuit season is almost ... Whisperer ® products has begun with a 35% discount. , ... estrogen. Many women get the dreaded cellulite even if they ... the skin where they have been stored as toxic lymph ... no easy fixes, a specific program that works to dissolve ...

(Date:5/21/2013)... Dallas, Texas (PRWEB) May 22, 2013 ... globally increasing meat production industry value chain. Most of ... the form of injectable, pellets, liquids, and powders. There ... in different quantities and concentrations depending upon the type ... acids, minerals, and vitamins that provide essential nutrition to ...

(Date:5/21/2013)... George Washington (GW) University School of Public ... launch of the Avance Center for the ... SPHHS, the Maryland Multicultural Youth Centers, the ... university-community partnership aims to address public health ... research, mutual capacity building and prevention efforts. ...

(Date:5/21/2013)... Medical Ministry International announced today that it has ... GreatNonprofits , the leading provider of user reviews about nonprofit ... 2013 Nonprofit,” says Samuel Smith, MMI CEO. This does ... and Staff serving in 22 countries around the world. This ... have seen our work first hand and wanted to tell ...

Breaking Medicine News(10 mins):Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2 Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3 Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3 Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2

[0] Colorado Takes a Huge Step toward Transforming the Family Dining Experience [0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"[0] Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com [0] GW launches center to address health disparities in the Latino immigrant community [0] Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org

... U.S. organ transplant system often fails to detect or fix ... according to the Los Angeles Times on Sunday. ... are usually kept a secret leaving patients and their families ... ,This nonprofit agency has been given the contract ...

... at the Indian Institute of Technology (IIT), Chennai, have ... them into cells, a// major step towards drug efficacy. ... that comprises a core of one material and a ... of delivering therapeutic molecules into cells and monitoring it ...

... 80% accuracy in prediction of the most effective drug against ... test that examines the// genetic material of a patient’s tumour. ... North Carolina report that this genomic test is useful in ... a particular cancer but also a combination of drugs. ...

... chefs are two to four times bigger than the government's ... contributing to increasing weight of their diners, the chefs believe ... ,These were the findings that were revealed by a ... the Obesity Society. ,A meal at a restaurant ...

... and bad news for women faced with the decision about ... is that screening mammography does reduce breast cancer mortality. The ... less likely to die of breast cancer than women who ... that women in a screened population are 30 percent more ...

... provide a scientific basis for eventual treatment, neurology researchers ... of a protein that// helps keep brain activity in ... to be an underlying reason for seizures and memory ... brain injury (TBI). ,“A traumatic brain injury ...

Cached Medicine News:Health News:Flaws Reported in overview of US organ transplants 2 Health News:Now, Silica Nanobubbles for Targeted Drug Delivery 2 Health News:Genomic tests for better cancer treatment 2 Health News:Portion Sizes in Restaurants Larger than Before 2 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3 Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4 Health News:How Brain Injury Leads to Seizures, Memory Problems 2

Flaws Reported in overview of US organ transplants Now, Silica Nanobubbles for Targeted Drug Delivery Genomic tests for better cancer treatment Portion Sizes in Restaurants Larger than Before Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis How Brain Injury Leads to Seizures, Memory Problems

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Diethyldithiocarbamate 2,4-Dichlorophenoxyacetic Acid, Urine 2,4-Dichlorophenoxyacetic Acid, Serum or Plasma Dibucaine